Marco Meglio

Patients treated with PC-rTMS showed almost no decline in the CDR-SB score, and presented a clear advantage in terms of cognitive functions in contrast to the worsening of the score observed in the sham group.

Among those on early highly-effective treatments, shorter disease duration and shorter time between first treatment and current treatment led to more patients achieving no evidence of disease activity.

Two weeks after natalizumab infusion, patients demonstrated significantly less central fatigue, with a trend for a reduction in supraspinal fatigue, among other notable findings.

Neurology News Network for the week ending October 28, 2022. [WATCH TIME: 4 minutes]

Using a prespecified noninferiority margin of 0.2 rate ratio, rituximab failed to distinguish itself from ocrelizumab on the primary end point of annualized relapse rate.

In the first of its kind ARISE study, treatment with dimethyl fumarate resulted in more than 80% reduction in risk of first demyelinating event relative to placebo.

Dose-dependent reductions in neurofilament light were observed at week 144 in both those who continued treatment from the double-blind period and those who switched from placebo.

Using a cohort of more than 2000 pregnancies, the data showed an extremely rare number of major congenital anomalies while on ocrelizumab, as most patients underwent live birth with no issue.

Using phenotypically “extreme” MS groups, annualized brain volume loss was higher in progressors vs non-progressors and was predicted by baseline GFAP and NfL levels.

The favorable annualized relapse rates for fingolimod over interferon beta-1a observed in the 2-year core phase continued in a 5-year open-label extension.

Over a median of 73.5 weeks of follow-up time, zero adjudicated relapses were observed for those with AQP4+ NMOSD on ravulizumab.

Among 43 cycles that achieved pregnancy, investigators observed decreases of annualized relapse rates from 0.26 to 0.09.

The neurologist at Allegheny Health Network’s Neuroscience Institute provided perspective on a new phase 3 trial assessing fenebrutinib, an investigational BTK inhibitor for relapsing multiple sclerosis.

The primary outcome of the study, 50% reduction in corticosteroid dosing, was achieved by 60% of patients on IGIV-C and 63.3% of those randomly assigned to placebo.

Over a 24-month treatment period, apitegromab-treated patients showed improvements on PEDI-CAT and PROMIS, measures of activities of daily living, and ESBBT, a muscle endurance measurement tool.

Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19.

Within 5 years after the index date, the lowest proportion of epilepsy diagnoses were among those treated with angiotensin receptor blockers and highest in those on ß-blockers and calcium channel blockers.

Changes in plasma pTau217 and GFAP levels from donanemab significantly correlated with percent change in amyloid plaque level as measured by amyloid PET imaging.

The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.

In a traditional placebo-controlled trial, Nerivio outperformed placebo in the reduction monthly migraine days and monthly headache days, regardless of chronic or episodic migraine status.

For patients who rolled over to the ARC-HD extension study from the previous First-HD trial, there was a 4.5-point reduction in mean chorea scores at week 8 that were maintained through week 145.

When asked which efficacious diagnostic or treatment options they hope to see in the future, a majority of physicians, especially specialists, expressed a desire to see more useful biomarkers, followed by more effective diagnostic tests overall.

Although neurodevelopmental disorders were common in those on antidepressants, the crude hazard ratios were substantially attenuated after adjustment for measured covariates and proxies for unmeasured covariates.

After a successful phase 1 study in which PTC518 reduced huntingtin protein by 30% to 50%, the company is pausing the US enrollment of its phase 2 study until additional data is provided to the FDA.

More than 40% of patients with ASPECTS scores between 4 and 5 treated with EVT showed functional outcome improvements, whereas slightly over 20% of those with scores between 0 to 3 demonstrated the same.

The adult neurologist at Allegheny Health Network discussed the ever-changing landscape of therapies for myasthenia gravis and shift toward more holistic disease management.

In a phase 2 study, fosgonimeton showed positive effects on measures of cognition, function, and neurodegeneration when taken as a monotherapy, prompting an unblinded interim analysis.

EDG-5506, an orally administered small molecule agent, showed nearly a 40% decrease in levels of serum creatine kinase in a phase 1b trial of adults with Becker muscular dystrophy.

In an open-label extension trial, tofersen showed significant reductions in SOD1 protein and neurofilament light over a 12-month period. It is now expected to be reviewed by the FDA by early Q2 2023.

The launch of the medication was done in phases, as wholesalers received first-line formulary coverage in September 2022, while a nationwide launch is expected in 2023.